CEL-SCI Corporation
CEL-SCI Study Shows CEL-2000 Vaccine Blocks Progression of Rheumatoid Arthritis
Published in Vaccine Weekly, March 10th, 2010
CEL-SCI Corporation (NYSE AMEX: CVM) and their scientific collaborators announced that the Company's CEL-2000 vaccine demonstrated that it is able to block the progression of rheumatoid arthritis (RA) in a mouse model. The results were published in the scientific peer-reviewed Journal of International Immunopharmacology (online edition) in an article titled "CEL-2000: A Therapeutic Vaccine for Rheumatoid Arthritis Arrests Disease Development and Alters Serum Cytokine / Chemokine Patterns in the Bovine Collagen Type II Induced Arthritis in the DBA Mouse Model" with lead author Dr. Daniel Zimmerman. The study was co-authored by scientists from CEL-SCI, Washington Biotech, Northeastern Ohio...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2010-03-10)
More Articles from Vaccine Weekly
- Wiley-Blackwell
Hepatitis B and C remain public health issue -- up to 5.3 million Americans infected - Bacillus Anthracis
Research on Bacillus anthracis described by J. Kern and colleagues - Bordetella
Study data from J.J. Gisel and colleagues update understanding of Bordetella - Gene Therapy
Research results from R. Pilankatta and co-authors update knowledge of gene therapy - Hepatitis B Virus
Research conducted at X. Causse and co-authors has provided new information about hepatitis B virus - Herpes Virus
New herpes virus study results from L. Ferreyra et al described - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
